Theravance Biopharma Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 116.87, 96.98, 92.76, 97.59, 103.56 ], "ebit_estimate": [ 58.73, 43.39, 47.68, 51.03, 62.69 ], "ebitda_estimate": [ null, null, null, null, null ], "net_income_estimate": [ 123.07, 41.11, 41.48, 47.44, 34.5 ], "per_share_eps_estimate": [ 2.5, 1.05, 0.83, 0.94, 1.03 ], "eps_nri_estimate": [ 2.36, 0.89, 0.92, 1.03, 1.09 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null ], "pretax_income_estimate": [ 174.07, 71.27, 55.16, 59.23, 74.03 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null ], "pettm_estimate": [ 6.79, 16.1, 20.36, 18.06, 16.49 ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "-6.09", "future_per_share_eps_estimate_growth": -30.12, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": -6.09, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": -29.16, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 21.8, 21.68, 42.58, 24.5, 32.5, 25.5, 63.5 ], "ebit_estimate": [ 1.88, 9.73, 35.83, null, null, null, null ], "ebitda_estimate": [ null, null, null, null, null, null, null ], "net_income_estimate": [ 3.06, 7.92, 89.81, 13.72, 21.84, 14.87, 52.91 ], "per_share_eps_estimate": [ 0.06, 0.18, 1.65, 0.26, 0.41, 0.28, 0.99 ], "eps_nri_estimate": [ 0.05, 0.17, 1.69, 0.26, 0.41, 0.28, 0.99 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ 2.78, 11.18, 111.98, null, null, null, null ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 7.89, 6.78, 6.52, 8.73, null, null, null ], "long_term_growth_rate_mean": 0, "long_term_revenue_growth_rate_mean": "-6.09", "future_per_share_eps_estimate_growth": -30.12, "future_eps_nri_estimate_growth": null, "future_revenue_estimate_growth": -6.09, "future_ebit_estimate_growth": null, "future_ebitda_estimate_growth": null, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": null, "future_pretax_income_estimate_growth": -29.16, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }